Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT2206 versus Stelara in moderate to severe plaque psoriasis
2020-004504-33Phase 3Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing BAT2206 with Stelara (2 arms). Primary endpoint: Percent change from baseline in Psoriasis Area and Severity Index score at Week 8. Started Feb 2021; status: completed.
02
Drugs
BAT2206ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2020-004504-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004504-33.